Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Streaming Finally Outpaces Traditional TV. The Leading Platform Might Surprise You. YouTube represented 12.5% of all television viewing in May-the highest share of TV for any streamer to date. The new ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...